- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.08. | Modus Therapeutics Holding AB: Modus Therapeutics publishes interim report for Q2 2026 | 215 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 26 August 2026: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes its interim report for the second quarter of 2026. The report is available on the company's... ► Artikel lesen | |
| 28.05. | Modus Therapeutics Holding AB: Annual General Meeting in Modus Therapeutics Holding AB (publ) | 195 | GlobeNewswire (Europe) | Modus Therapeutics' Annual General Meeting on 28 May 2026 resolved in accordance with the following:
That no dividend would be paid.To discharge the board members and the managing director from liability... ► Artikel lesen | |
| 26.05. | Modus Therapeutics Holding AB: Modus Therapeutics publishes interim report for Q1 2026 | 203 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 26 May 2026: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes its interim report for the first quarter of 2026. The report is available on the company's website... ► Artikel lesen | |
| MODUS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 25.02. | Modus Therapeutics Holding AB: Modus Therapeutics publishes year-end report for 2025 | 827 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 25 February 2026: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes year-end report for 2025. The report is available on the company's website (www.modustx.com)... ► Artikel lesen | |
| 10.12.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia | 347 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in the phase 2a... ► Artikel lesen | |
| 26.11.25 | Modus Therapeutics Holding AB: Modus Therapeutics publishes Interim report for the third quarter 2025 | 553 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 26 November 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the third quarter of 2025. The report is available on the company's... ► Artikel lesen | |
| 04.11.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia | 345 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate... ► Artikel lesen | |
| 03.11.25 | Modus Therapeutics Holding AB: Modus Therapeutics receives regulatory approval for Part 2 of the Phase IIa study in CKD-with anemia | 371 | GlobeNewswire (Europe) | Stockholm, Sweden - November 3, 2025- Modus Therapeutics Holding AB (publ) ("Modus" or the "Company") announces that the competent authorities in Italy have approved the Company's dose selection for... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,605 | -1,83 % | EQS-News: NanoRepro AG: Deutsche Kosmetikwerke AG wird Tochterunternehmen - Aktientausch sichert NanoRepro die Stimmrechtsmehrheit - Plattform-Struktur nimmt weiter Form an | EQS-News: NanoRepro AG
/ Schlagwort(e): Beteiligung/Unternehmensbeteiligung/Strategische Unternehmensentscheidung
NanoRepro AG: Deutsche Kosmetikwerke AG wird Tochterunternehmen... ► Artikel lesen | |
| MARINOMED BIOTECH | 3,850 | -100,00 % | Original-Research: Marinomed Biotech AG (von First Berlin Equity Research GmbH): Einstellung der Coverage | Original-Research: Marinomed Biotech AG - from First Berlin Equity Research GmbH
24.09.2026 / 17:08 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| REPLENISH NUTRIENTS | 0,171 | +1,79 % | Replenish Nutrients: SRC's Proposed $15M Strategic Investment Supports a 5x Step-Up in Owned Capacity | Company: Replenish NutrientsListings: CSE Canada, Frankfurt and US OTCTickers: ERTH / VVIVF / WIMNMarket cap at time of publication: $38 MCADStock price at time... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 2,905 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates | Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward... ► Artikel lesen | |
| NOVABRIDGE BIOSCIENCES | 1,190 | 0,00 % | NovaBridge Biosciences: NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director | Martin Dewhurst appointed as independent director and member of the Audit and Compensation CommitteesVeteran healthcare executive brings more than 30 years of leadership, governance, and strategic... ► Artikel lesen | |
| GENEURO | 0,027 | 0,00 % | NRx Pharmaceuticals, Inc.: GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS) | Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the "dark genome" of all people. K Env... ► Artikel lesen | |
| QIAGEN | 40,405 | +5,80 % | Microsoft, Newron, Pyrum, Qiagen, Börse München - das 4investors.de-Weekend | Was hat Anleger am Wochenende bewegt? Hier sind die 4investors.de-Berichte vom Wochenende mit spannenden Aktien-Stories zu Microsoft, Newron, Pyrum, Qiagen sowie der Börsenpresseschau der Börse München.... ► Artikel lesen | |
| CG ONCOLOGY | 67,38 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 39,640 | 0,00 % | Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days | ||
| TARSUS PHARMACEUTICALS | 73,00 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting | ||
| PRAXIS PRECISION MEDICINES | 295,78 | +0,09 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VERA THERAPEUTICS | 30,420 | 0,00 % | Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 | BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,755 | 0,00 % | Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft | DJ Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft
Von Elias Schisgall
DOW JONES--Astrazeneca investiert im Rahmen einer erweiterten Partnerschaft 2 Milliarden... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,225 | -0,06 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 10,500 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk | In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized... ► Artikel lesen |
MODUS THERAPEUTICS HOLDING AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,022 Euro und damit +0,91 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MODUS THERAPEUTICS HOLDING AB finden Sie auf Wallstreet Online.